CMXC CELL MEDX CORP
- 0.021000
- -0.000100-0.47%
CELL MEDX CORP News
Cell MedX Corp. Closes Private Placement Financing
Cell MedX Corp. Announces Resignation of Director
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commer
Cell MedX Corp. Appoints Dr. George Adams as Chairman of the Board
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commer
Over $6M Bet On This Tech Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed higher by over 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
Cell MedX Corp. Announces New CEO and Directors and Debt Settlement
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commer
Cell MedX Corp. Announces Full Revocation of British Columbia Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - November 27, 2023) - Cell MedX Corp. ("Cell MedX" or the "Company") (OTC Pink: CMXC) announces that on November 22, 2023, the British Columbia Securitie
Cell MedX Corp. Appoints Audit Committee and Accepts Resignation of Chief Operating Officer
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2023) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commerc
Cell MedX names new CEO
Cell MedX (OTCQB:CMXC) named Dwayne Yaretz as its new CEO, to succeed McEnulty, on Wednesday.The biotech company told Yaretz has held leadership roles in private and public companies."I am excited to
Cell MedX Corp. Appoints Mr. Dwayne Yaretz as CEO and Director
Carson City, Nevada--(Newsfile Corp. - April 27, 2022) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of
Big data and events in the week from October 25 to 31: the three major central banks announced interest rate decisions, and the Federal Reserve entered a period of silence.
Original title: blockbuster data and events in the week of October 25-31: the three major central banks announced interest rate decisions, and the Federal Reserve entered a period of silence. source: Huitong net in the week of October 25-31, the market will welcome a series of blockbuster data and events. In terms of events, pay attention to the interest rate decisions of the Bank of Canada, the Bank of Japan and the European Central Bank. Data, the third quarter of the United States GDP, the United States PCE, EIA, first request, personal expenditure, euro zone GDP, CPI and so on will be released one after another, investors need to pay close attention. It is worth noting that the Federal Reserve will enter a period of silence next week, as the Federal Reserve will hold a meeting in the early morning of November 4.
Nike Inc fell by more than 4% before trading. Q1 revenue was lower than market expectations.
Nike Inc (NKE.N) fell more than 4% before trading. Q1 revenue fell below market expectations, as delays in production and delivery prevented the company from meeting the strong demand for shoes and sportswear in a timely manner.
The RBA maintains its plan to reduce the size of its bond purchases and keeps its key interest rate unchanged at 0.1%.
The Reserve Bank of Australia left its key interest rate and three-year Treasury yield target unchanged at 0.10% on Tuesday, in line with expectations. In a statement after the August policy meeting, Philip Lowe, chairman of the RBA, said the RBA would continue to buy A $5 billion of bonds a week until early September and then reduce it to A $4 billion a week, at least until mid-November. The council will maintain its flexibility on the scale of bond purchases. The plan will continue to be reviewed in the light of economic conditions and outbreaks and their impact on expected progress towards the achievement of full employment and inflation targets. Australian Federation
ECB policymaker De Cos says bond buying flexibility should be maintained after the pandemic
ECB Governing Council member Pablo Hernandez de Cos said the ECB should consider retaining some flexibility in the emergency bond purchase plan when transitioning to other asset purchases after the COVID-19 crisis. The Spanish central bank governor said on Tuesday that “the main lesson learned” from the plan is that shifting purchasing preferences to the areas most needed in the economy can significantly improve purchasing effectiveness and efficiency. “It is therefore advisable to keep some elements of flexibility when discussing our future purchasing plans,” he said. 1.85 trillion euro (2.2 trillion US dollars) epidemic prevention debt purchase plan
Analysis
Price Target
No Data
